VAUGHAN, Ontario / Jan 03, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders will participate in a fireside chat with investors at the 42nd Annual J.P. Morgan Healthcare Conference on Jan. 8, 2024, at 11:15 a.m. PT (2:15 p.m. ET). Other company executives, including Chief Financial Officer Sam Eldessouky and Global Pharmaceuticals and International Consumer President Andrew Stewart, will also participate in the conference.
A live webcast and audio archive of the event will be available on the Investor Relations page of the Bausch + Lomb website: https://ir.bausch.com/investors/events-presentations.
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.
© 2024 Bausch + Lomb.
Last Trade: | US$13.88 |
Daily Change: | -0.32 -2.25 |
Daily Volume: | 385,989 |
Market Cap: | US$4.910B |
June 04, 2025 May 21, 2025 May 07, 2025 April 30, 2025 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load